NCT05168683 - Scintigraphy Study in Healthy Volunteers to Characterize the Performance of ALLN-346 Tablets | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

January 11, 2022

Primary Completion Date

February 23, 2022

Study Completion Date

February 23, 2022

Conditions

HyperuricemiaGout

Interventions

DRUG

Each ALLN-346 treatment will be radiolabelled to contain 4 MBq 99mTc at time of dosing with light meal

Dosing or radiolabelled ALLN-346 fast or slow release tablets or capsules. Scintigraphic images will be taken

DRUG

Each ALLN-346 treatment will be radiolabelled to contain 4 MBq 99mTc at time of dosing in fasted/fed state

Selected dosing of Part One treatments in fasted and/or fed states

Trial Locations (1)

BDD Pharma Ltd Bio-Imaging Centre Within Glasgow Royal Infirmary, Glasgow